Title
Characterization of <tex>$[^{99m}Tc]$</tex>duramycin as a SPECT imaging agent for early assessment of tumor apoptosisCharacterization of <tex>$[^{99m}Tc]$</tex>duramycin as a SPECT imaging agent for early assessment of tumor apoptosis
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Research group
Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO)
Publication type
article
Publication
,
Subject
Human medicine
Computer. Automation
Source (journal)
Molecular imaging and biology. -
Volume/pages
17(2015):6, p. 838-847
ISSN
1536-1632
ISI
000364941700013
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
Purpose We investigated the usefulness of [99mTc]duramycin for monitoring early response to cancer therapy in mice, with an eye towards clinical translation. Procedures [99mTc]Duramycin was injected in healthy CD1−/− mice to estimate human [99mTc]duramycin radiation dose. [99mTc]Duramycin single-photon emission computed tomography (SPECT) imaging of apoptosis was evaluated in a mouse model of colorectal cancer treated with irinotecan and validated ex vivo using autoradiography, cleaved caspase-3, and TdT-mediated dUTP nick-end labeling (TUNEL) histology of the tumors. Results The mean effective dose was estimated to be 3.74 × 10−3 ± 3.43 × 10−4 mSv/MBq for non-purified and 3.19 × 10−3 ± 2.16 × 10−4 mSv/MBq for purified [99mTc]duramycin. [99mTc]Duramycin uptake in vivo following therapy increased significantly in apoptotic irinotecan-treated tumors (p = 0.008). Radioactivity in the tumors positively correlated with cleaved caspase-3 (r = 0.85, p < 0.001) and TUNEL (r = 0.92, p < 0.001) staining. Conclusion [99mTc]Duramycin can be used to detect early chemotherapy-induced tumor cell death, and thus, may be a prospective candidate for clinical SPECT imaging of tumor response to therapy.
Full text (open access)
https://repository.uantwerpen.be/docman/irua/ce879f/e6976db1.pdf
E-info
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364941700013&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364941700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364941700013&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle